Literature DB >> 31934027

miR-101-3p sensitizes hepatocellular carcinoma cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy.

Wenping Sun1, Qiang Zhang2, Zhiwei Wu3, Na Xue3.   

Abstract

BACKGROUND: Increasing evidence has shown that autophagy can contribute to drug resistance. Whether microRNA-101-3p (miR-101-3p) participates in oxaliplatin (OXA) resistance via modulating Beclin-1-mediated autophagy in hepatocellular carcinoma (HCC) has not been reported.
METHODS: OXA-resistant Huh7 cells (Huh7/OXA) or HepG2 cells (HepG2/OXA) and OXA-sensitive Huh7 or HepG2 cells were treated with OXA in various concentrations. The expressions of miR-101-3p and Beclin-1 were monitored using qRT-PCR. Western blot was used to evaluate cell autophagy. Cell viability and the IC50 of OXA were determined using an MTT assay. Cell apoptosis was evaluated by flow cytometry. A luciferase reporter assay was introduced to confirm the relationship between miR-101-3p and Beclin-1.
RESULTS: miR-101-3p was decreased in HCC resistant tissues and cells. Moreover, an increased expression of miR-101-3p reduced cell viability and the IC50 of OXA, and it promoted cell apoptosis in Huh7/OXA and HepG2/OXA cells. miR-101-3p negatively modulated the expression of Beclin-1. Interestingly, the overexpression of Beclin-1 receded the effect of the ectopic expression of miR-101-3p in OXA-resistant HCC cells. In OXA-sensitive Huh7 and HepG2 cells, OXA significantly increased the expressions of LC3 and Beclin-1, and it decreased the abundance of p62. Furthermore, OXA markedly blocked cell viability, which was exacerbated by the introduction of the autophagy inhibitor CQ. Additionally, the elevated expression of miR-101-3p suppressed cell autophagy by inhibiting the expression of LC3 and Beclin-1 and facilitating the expression of p62.
CONCLUSION: miR-101-3p is responsible for the sensitivity of HCC cells to OXA by inhibiting Beclin-1-mediated autophagy. IJCEP
Copyright © 2019.

Entities:  

Keywords:  Beclin-1; autophagy; hepatocellular carcinoma; miR-101-3p; oxaliplatin

Year:  2019        PMID: 31934027

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  6 in total

1.  Comprehensive Analyses of MELK-Associated ceRNA Networks Reveal a Potential Biomarker for Predicting Poor Prognosis and Immunotherapy Efficacy in Hepatocellular Carcinoma.

Authors:  Yu Liu; Rongkuan Li; Xiaobo Wang; Zuguang Xue; Xiaozhou Yang; Bo Tang
Journal:  Front Cell Dev Biol       Date:  2022-05-27

2.  Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib.

Authors:  Flavia Fondevila; Carolina Méndez-Blanco; Paula Fernández-Palanca; Tania Payo-Serafín; Jos van Pelt; Chris Verslype; Javier González-Gallego; José L Mauriz
Journal:  Int J Mol Sci       Date:  2021-10-29       Impact factor: 5.923

3.  Effects of runt-related transcription factor 2 (RUNX2) on the autophagy of rapamycin-treated osteoblasts.

Authors:  Cheng Ren; Yibo Xu; Hongliang Liu; Zhimeng Wang; Teng Ma; Zhong Li; Liang Sun; Qiang Huang; Kun Zhang; Chengcheng Zhang; Yu Cui; Qian Wang; Yao Lu
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

4.  Non-coding ribonucleic acid-mediated CAMSAP1 upregulation leads to poor prognosis with suppressed immune infiltration in liver hepatocellular carcinoma.

Authors:  Wenwen Wang; Jingjing Zhang; Yuqing Wang; Yasi Xu; Shirong Zhang
Journal:  Front Genet       Date:  2022-09-21       Impact factor: 4.772

5.  A microRNA delivery carrier for hepatic carcinoma therapy using layer-by-layer self-assembled mesenchymal stem cells.

Authors:  Chunmin Li; Xin Li; Fengsheng Li; Dawei Wang; Jin Wang; Tao Yan; Bo Sun; Hualiang Ren
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241

6.  Up-regulation of microRNA miR-101-3p enhances sensitivity to cisplatin via regulation of small interfering RNA (siRNA) Anti-human AGT4D and autophagy in non-small-cell lung carcinoma (NSCLC).

Authors:  Dong Cui; Yu Feng; Rulin Qian
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.